This post was originally published on this site Women with early, low-risk hormone receptor-positive breast cancer are significantly less likely to see their disease return if given radiation therapy and hormone therapy following surgery, according to a trial that followed hundreds of women for nearly 10 years. Specifically, the trial found that whole breast irradiation…
This post was originally published on this site Dutch researchers have developed a new experimental protocol that allowed them to culture mini ovarian cancers (organoids) in the lab that retained their three-dimensional structure and captured the cellular diversity seen in patients. These organoids, which mimic the cellular environment and treatment responses in patients, may be…
This post was originally published on this site OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in Chicago, Illinois. Inductees are being recognized for furthering the field of oncology, including multiple myeloma, through research and clinical practices. “We are looking…
This post was originally published on this site I don’t like to think about death, much less write about it. Over 11 years as a follicular lymphoma patient, I’ve gotten pretty good at not thinking about it. But now and then, something happens that makes it unavoidable. Like when a famous person with lymphoma, such…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company announced. Specifically, the FDA’s approval is for patients who had residual disease after their pre-surgery treatment, which included a…
This post was originally published on this site Men with low-risk prostate cancer can safely receive a single high dose of brachytherapy — a type of radiation therapy delivered directly into the tumor within a few minutes — as an alternative treatment for their condition, a study shows. After three years of treatment, 100% of…
This post was originally published on this site People with high exposure to sunlight or ultraviolet radiation are significantly less likely to develop non-Hodgkin’s lymphoma compared to those with low exposure, but vitamin D levels in the body have no impact on disease incidence, a new study shows. The study, “Vitamin D status and risk…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with BRCA-mutated advanced ovarian cancer, AstraZeneca and Merck announced. Specifically, the recommendation is for women who are responding, partially or completely,…
This post was originally published on this site ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and anti-tumor activity after large-scale manufacturing, a study says. The preclinical findings were reported in the study, “Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA…
This post was originally published on this site Gritstone Oncology is advancing its investigational immunotherapy Slate into Phase 1 clinical studies sooner than planned, and expects patient enrollment to start as early as mid-2019, the company announced. This follows feedback from the U.S. Food and Drug Administration (FDA), which will review toxicity data from Granite…
